MedTrace Logo

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

NCT01732822 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 13885

Last updated 2017-10-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.

Conditions

Interventions

DRUG

Ticagrelor

Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets

DRUG

Clopidogrel

Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets

Sponsors & Collaborators

Principal Investigators

  • William R Hiatt, MD · University of Colorado School of Medicine

  • Peter Held, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-04
Primary Completion
2016-09-26
Completion
2016-09-26

Countries

  • United States
  • Argentina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Czechia
  • France
  • Germany
  • Hungary
  • Italy
  • Japan
  • Mexico
  • Netherlands
  • Philippines
  • Poland
  • Romania
  • Russia
  • Slovakia
  • South Korea
  • Spain
  • Sweden
  • Thailand
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01732822 on ClinicalTrials.gov